May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Efficacy of Sub-Tenon Triamcinolone Acetonide to Prevent Macular Edema After Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Author Affiliations & Notes
  • S. Mizunoya
    Ophthalmology, Teikyo University Chiba Medical Center, Ichihara, Japan
  • H. Kanai
    Ophthalmology, Teikyo University Chiba Medical Center, Ichihara, Japan
  • Y. Kanaya
    Ophthalmology, Teikyo University Chiba Medical Center, Ichihara, Japan
  • K. Ikeda
    Ophthalmology, Teikyo University Chiba Medical Center, Ichihara, Japan
  • A. Hosoda
    Ophthalmology, Teikyo University Chiba Medical Center, Ichihara, Japan
  • H. Abe
    Ophthalmology, Teikyo University Chiba Medical Center, Ichihara, Japan
  • H. Kidahashi
    Ophthalmology, Teikyo University Chiba Medical Center, Ichihara, Japan
  • M. Suzuki
    Ophthalmology, Teikyo University Chiba Medical Center, Ichihara, Japan
  • Footnotes
    Commercial Relationships  S. Mizunoya, None; H. Kanai, None; Y. Kanaya, None; K. Ikeda, None; A. Hosoda, None; H. Abe, None; H. Kidahashi, None; M. Suzuki, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 3491. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Mizunoya, H. Kanai, Y. Kanaya, K. Ikeda, A. Hosoda, H. Abe, H. Kidahashi, M. Suzuki; Efficacy of Sub-Tenon Triamcinolone Acetonide to Prevent Macular Edema After Panretinal Photocoagulation for Proliferative Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2008;49(13):3491. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the effectiveness of sub-tenon triamcinolone acetonide (STTA) in preventing macular edema after panretinal photocoagulation (PRP) for proliferative diabetic retinopathy.

Methods: : Twenty milligrams of TA was injected into the posterior sub-tenon’s capsule before panretinal photocoagulation in 16 eyes of 10 patients (age, mean 55 years; range, 40 to 69 years) with proliferative diabetic retinopathy. Patients had a complete ophthalmic evaluation including visual acuity and optical coherence tomography (OCT) at baseline and at follow-up visits.

Results: : The follow-up period was >3 months in all eyes. The mean best-corrected visual acuity improved from 0.30 at baseline to 0.23 logMAR units at 3 month after STTA. The mean foveal thickness (FT) was 361±170 µm at baseline and 363±183 µm at 3 month. After 3 month, 5 eyes of 4 cases had a reduction of FT >20%, 8 eyes of 5 cases did not change (<±20%), and 3 eyes of 3 cases had an increase in the FT >20% compared to the baseline. No adverse side-effects were observed following TA.

Conclusions: : Posterior sub-Tenon’s capsule injection of 20 mg TA performed before PRP for proliferative diabetic retinopathy may prevent the PRP-induced macular edema and a reduction of vision.

Keywords: diabetic retinopathy • macula/fovea • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×